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Mesothelioma is a malignancywith poor prognosis, with an average 5-year survival rate being less than 9%. This type of cancer is
almostexclusivelycausedbyexposure toasbestos.Alongexposurecancausemesotheliomaandsocanshortones,aseachexposure
is cumulative. We report a case of a 26-year-old male who was exposed to asbestos during his primary schoolyears from the age of
6 to 12. Although the tumor mainly aﬀects older men who in their youth were occupationally exposed to asbestos, malignant
mesothelioma can also occur in young adults. A medical history was carefully taken and asbestos exposure was immediately
mentioned by the patient. We conducted biopsy on the right supraclavicular lymph node. The patient was not a candidate for
surgery,andchemotherapytreatmentwasinitiated.Whilepatient’schemotherapyisstillongoing,noothersimilarcasesofstudents
or teachers have been traced up to date from his school. The school building was demolished in January 2009.
1.Introduction
Asbestos deﬁnes a group of naturally occurring mineral
silicates, which are used for various commercial applica-
tions including ﬁreprooﬁng and insulation. Asbestos readily
breaks into small dust-like ﬁbers, which are easily inhaled,
resulting in a variety of diseases of the respiratory system
including asbestosis, lung cancer, and malignant pleural
mesothelioma (MPM) [1, 2]. To date, asbestos has largely
been banned from work and home environments, but
many countries still produce and export asbestos under
strict regulations and at reduced levels [3, 4]. Asbestos-
related lung diseases will remain a major health concern,
mainly due to the long latency between exposure and
disease development [4, 5]. Once asbestos exposure has
occurred, there is no secondary prevention of chest diseases
or prophylactic treatment available. There is a direct causal
relation between the degree of asbestos exposure and MPM
[6, 7]. While the risk of lung cancer slowly declines after
smoking cessation, the risk of MPM progressively increases
with time [8]. Pleural plaques and MPM share the same
etiology but have a diﬀerent latency period (10–20 years for
plaques, 20–40 years for MPM), and even though plaques
are not regarded as a risk factor of MPM, the presence
of pleural plaques provides a risk indicator and thus a
window of opportunity for MPM diagnosis [9–14]. The
diagnosis is further complicated by the wide variety of
histological appearances that mesotheliomas may assume
and the large number of entities that can simulate this
appearance. Therefore, a diagnosis of mesothelioma should
be made only after cautious consideration of the available
information.
2.Case Report
A-26-year-old male attended the emergency department
with intense pain, of a right-sided supraclavicular lump,
with signs of visible inﬂammation. The history of the2 Case Reports in Medicine
L C
Figure 1: Enlarged supraclavicular node.
presented lymph node revealed that the swollenness was
initially presented three months ago. In spite of the gradual
enlargement, the patient did not seek any medical advice or
treatment. On chest palpation, there was edema, redness,
and lymphatic obstruction of the right tracheal position,
pectoralis, shoulder, and humerus. There was no abnor-
mality of chest expansion and symptoms of fever, night
sweats, and infection. The patient complained of fatigue that
gradually escalated during the past 3 weeks, but without
any weight loss. On lung percussion, the right side was
equal to the left and resonant. On lung auscultation, there
were vesicular breath sounds and there was no reduced air
entry, no crackles, no wheeze, and no crepitating or rub.
Clinical examination of the abdomen revealed ascites, and
abdominal U/S conﬁrmed peritoneum eﬀusion (exudate).
There were no other pathologic ﬁndings on cardiovascular
and neurological examination. Past medical history did
not reveal any previous medical problems or operations.
The patient was on no regular medication. Social history
excluded smoking, illegal drug, and alcohol abuse. The chest
X-ray showed no pathology. On further questioning, the
patient mentioned that his school building was constructed
with asbestos-containing materials and that it was recently
demolishedby thelocal prefectureauthorities. This exposure
was the only asbestos exposure he had during his life. During
hospitalization,he developedan acuteright-sided chestpain.
His ECG was normal; however, the CT scan of the trachea
demonstrated an enlarged supraclavicular node (Figure 1),
and on the CT scan of the thorax (Figure 2), nodes between
the vessels of the upper mediastinum were demonstrated.
In addition, small pleural eﬀusion and an epiphrenic node
on the right were observed (Figure 3). Further evaluation
of the patient was done to evaluate the local extension of
the lesion beginning from the right supraclavicular node to
the right pectoralis with MRI. The MRI of the upper thorax
revealed that the lesion had irregular contour, involving




Figure 2: Axial enhanced CT-image of paratracheal right-sided
mass and pleural eﬀusion.
possibility of mesothelioma was considered, as there were no
other clinical or laboratory ﬁndings supporting any speciﬁc
diagnoses. Diﬀuse malignant mesothelioma arises from the
mesothelium. It can occur in any of the body cavities
covered by mesothelium, most frequently in the pleura or
peritoneum, but also in the pericardium or tunica vaginalis
testis [15]. Also a similar case with malignant mesothelioma
that inﬁltrated the pectoralis has recently been published
[16].
Although thoracoscopy is usually the routine procedure
to obtain a pleural biopsy, an alternative method of biopsing
the enlarged supraclavicular lymph node (Figure 1)w a s
preferred to conﬁrm the diagnosis of mesothelioma [13,
14]. The result of the biopsy was positive for malignant
metastatic mesothelioma. A second biopsy was performed
and the sample was sent to another pathology department,
in order to exclude any possible error. The result of the
second biopsy was also positive for metastatic malignant
mesothelioma. Immunohistochemistry method was positive
for the following staining proﬁle: AE1/AE3, WT-1, and
calretinin, D2-40 and negative for CEAp,TTF-1. The patient
was stage IV according to the International Mesothelioma
Group (IMIG) [17]. Unfortunately none of the pathology
laboratories were able to deﬁne the subtype of the mesothe-
lioma (epithelial, sarcomatoid, or mixed), which is a very
important prognostic factor. The patient refused to undergo
another diagnostic biopsy, since it was explained to him
the extent of the disease and the cost eﬀect of another
biopsy, since it would not change his therapeutic treatment
approach. The staging was done with CT scan of the thorax,
abdomen, brain, and bone scintiscan. Due to the initial
extent of the disease (supraclavicular lymph node), it was
decided not to perform further diagnostic evaluation (e.g.,
PET scan).
The treatment of malignant pleural mesothelioma
(MPM) has evolved in the past 20 years. Treatment selection
was based on tumor stage and patient’s overall medicalCase Reports in Medicine 3
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Figure 3: Axial enhanced CT-image of the lower part of the
chest (mediastinal window) shows small pleural eﬀusion and an
epiphrenic node at the right. Ascites and thickness of the right crus
are also noticed.
condition. Two randomized trials have now established
the combination of cisplatin and an antifolate pemetrexed
or raltitrexed as the standard in the systemic therapy for
mesothelioma [18, 19]. In a published study on those who
actually received chemotherapy, immediate treatment was
associated with a signiﬁcantly longer time to symptomatic
p r o g r e s s i o na n dat r e n dt oi m p r o v e do v e r a l ls u r v i v a l :6 6 %
at 1 year compared to the “delayed” patients (36%), whose
quality of life was less well maintained. Whether the true
improvement in median survival with chemotherapy will be
in the observed magnitude of 3-4 months is doubtful. As is
thecase inadvancedNSCLC,theestimatedmedian improve-
ment in a general mesothelioma population eligible for
platinum-based chemotherapy will probably average 8–10
weeks [20]. Although, strictly speaking, head-to-head com-
parisons between cisplatin/pemetrexed, cisplatin/raltitrexed,
MVP, or vinorelbine need to be conducted, it is foreseeable
that, also in analogy with NSCLC, none of these regimens
will prove to be superior and that criteria other than
outcome will become decisive: toxicity, compliance, and ease
of administration. We chose to treat the patient with car-
boplatin, gemcitabine and, pemetrexed as reported in other
studies, due to the excellent performance status but also
for psychological reasons to encourage the young patient.
The multimodality treatment protocols have achieved a
median survival of 19 to 46 months depending on the stage,
histology,andcompletenessofthesurgicalresection[21–25].
In a certain subgroup ofpatientswith epithelial histology, no
lymph node involvement, and complete surgical resection,
the results were even more favorable with occasional long-
term survival [21]. During the evolution of the treatment
of MPM, successful local control of the disease with accept-




Figure 4: Axial stir (short-tau-invesion-recovery) MR image of the
upper thorax demonstrates a lesion located in the right part of the
anterior thoracic wall and shows increased inhomogeneous signal
intensity. The lesion has irregular contour, involving the major
pectoralis muscle. Inside the lesion, a node is noticed.
extra pleural pneumonectomy (EPP) and adjuvant high-
dose hemithoracic irradiation [22, 23, 26]. The feasibility
of high-dose hemi thoracic irradiation following EPP was
investigatedinaphaseIItrialfrom MemorialSloanKettering
Cancer center with local control rates over 90% [22, 26]. In
a similar study from MD Anderson Cancer center, despite
successful local control, distant recurrence, especially in
the abdomen, was a major problem in long term [27].
The patient received six cycles of chemotherapy with initial
response. A decrease in mediastinum and supraclavicular
lymphnodeswasobserved.Theinﬂammation andlymphatic
obstruction on the right supraclavicular area was yielded.
At his last followup, 2 months after his last chemotherapy
session, the patient was referred to our department with
extensive ascites, despite the stable disease on the thorax. It
was decided to initiate chemotherapy with carboplatin AUC
5.5 and docetaxel 100mg/m2, not only based on our center’s
experience and clinical practice, but also based on previous
published trials [28, 29].
3.Discussion
The widespread use of asbestos during the 20th century has
produced a legacy of ill-health, death, and contamination
w h i c hw i l le n d u r ew e l li n t ot h ec u r r e n tc e n t u r y .M e s o t h e -
lioma is an incurable but rare disease with an incidence in
industrialized countries ranging from 5 to 50/million/year
[30]. This cancer is almost exclusively caused by exposure
to asbestos. In 1960, Mossman and Gee reported the ﬁrst
conclusiveassociationbetweenasbestos exposureandpleural
mesothelioma [31]. Pleural mesotheliomas, which represent
the most common form, have a male to female ratio of
about 5 to 1 [32]. Although the tumor mainly aﬀects older4 Case Reports in Medicine
men who in their youth were occupationally exposed to
asbestos, malignant mesothelioma can also occur in children
[33]. Epidemics of asbestos illness have been reported in
industrialized countries for many years; now data are being
collated, which document an escalation of these diseases in
developing countries such as Brazil, Thailand, and Egypt. In
Greece, 2% of the recognized occupational morbidity has
been attributed to pleural mesothelioma (a single case of a
sheet-metal worker in 2001 that was ﬁnally recognized as an
occupational disease); however, there is a longstanding issue
of underreporting and under-recognition of occupational
diseases [34, 35]. However, we should be aware of the fact
thatMPM canalsooccurwithoutexposuretoasbestos ﬁbres,
but in our case the exposure of the patient to asbestos ﬁbres
was certain.
Until 1995, Greece was amongst the world’s top seven
suppliers of asbestos, producing 100,000tonnes of chrysotile
every year with up to 300,000tonnes a year of Greek and
imported asbestos processed at various asbestos-cement fac-
tories. Asbestos-containing brakes and ﬁreprooﬁng materials
were also produced in Greece. In 1993, the use of blue
asbestos (crocidolite) was banned by law (article 1154/93);
on December 31, 2004, Greece became the last of the 15
European Union (EU) Member States to ban the use of
all forms of asbestos as per the EU Directive [34, 36].
There are six types of asbestos ﬁbrous silicates (actinolite,
asbestos grunerite, anthophyllite, chrysotile, crocidolite, and
tremolite), all capable of causing mesothelioma; however,
only three types have been used commercially. White
asbestos (chrysotile), brown asbestos (amosite), and blue
asbestos (crocidolite) have been used in the construction
of school buildings. Amphiboles (crocidolite and amosite)
are more potent than chrysotile alone [37]. Asbestos was
most commonly used in schools as insulation and in
building materials. It has been used in ﬂoor and ceiling tile,
walls, acoustic insulation/attenuation, doors, blackboards,
cement asbestos pipe, corrugated paper pipe wrap, dec-
orative insulation, pipe and boiler insulation, and spray-
applied ﬁreprooﬁng [38]. The amount of asbestos in these
products varies widely from 1% to 100%, with pipe and
boiler insulation containing more asbestos than any other
building material. As the precise amount of asbestos in a
product cannot often be determined on the basis of its label
or by contacting the manufacturer, its positive identiﬁcation
requires analysis of samples by a qualiﬁed laboratory.
Asbestos-containing materials become hazardous when,
due to accidental damage, vandalism, or deterioration over
time,theyreleaseﬁbersthatremainintheairformanyhours.
Heaps of asbestos wastes with breaks of cement were col-
lected. Although the association between asbestos exposure
and the development of malignant pleural mesothelioma
(MPM) is well recognized, the relationship between asbestos
contents by ﬁber type and the risk of development for MPM
remains unclear. An association between and evaluation of
asbestos and ﬁber-type concentration were made in a small
study [39]. To elucidate the relation between the pulmonary
asbestos-ﬁber contents by ﬁber type and development of
MPM, further investigation is considered necessary. In our
c a s e ,w ed i dn o tt r yt om a t c ht h et i s s u eﬁ b e r so ft h eb i o p s y
to the ﬁbers used for the school materials since we did not
have access to the school debris. Finally, we do not have data
about the incidence of mesothelioma in other individuals
that were exposed to the building, due to the long time that
has passed since our patient has lost contactwith his teachers
and classmates.
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